Although treatment outcomes have improved, relapsed or refractory chronic lymphocytic leukemia (RRCLL) is still not curable with standard therapies and has a poor prognosis. Long-term data from patients with CLL who have received chimeric antigen receptor T-cell therapy against CD19 (CART-19) are now available.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Asthma in adults
When do pneumology specialists come into play?
- Cutaneous lupus erythematosus
From diagnostic workup to successful treatment
- Guideline update
Dietary recommendations for Crohn’s disease and colitis
- Circadian rhythm during Ramadan
Disturbed sleep patterns lead to metabolic stress
- Case Report
Breast cancer metastases in the bladder
- Findings from the ALS Symposium 2024 in Montreal
Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
- Efficacy, mechanism of action and clinical effects
Garlic and high blood pressure
- Moderate to severe chronic hand eczema